Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway

Dogwood Therapeutics, Inc.

2025-Q1 EPS reported -$8.45

Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.
Halneuron Phase 2b CINP study initiated; interim data readout expected Q4 2025.
$19.5M loan from CK Life Sciences affiliate converted to equity; $4.8M gross common stock raise.
Cash and equivalents of $17.5M provides operational runway through Q1 2026.
Regained Nasdaq compliance with minimum stockholders' equity of $2.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.